Furiex (FURX) Confirms Takeda's Resubmissions of Alogliptin, Combo Alogliptin, Pioglitazone NDAs to FDA
Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today confirmed that Takeda Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Takeda Global Research & Development Center, Inc. has resubmitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for alogliptin and fixed-dose combination therapy alogliptin and pioglitazone for the treatment of type 2 diabetes in adults. Takeda anticipates the applications will be reviewed within the next six months. These NDAs were resubmitted in response to a complete response letter Takeda received from the FDA on April 25, 2012.
You May Also Be Interested In
- Auxilium Pharma (AUXL) Slumps; Court Grants Summary Judgment in Testin Gel Suit
- PayPal Reported Slower Mobile Payment Growth for Cyber Monday (EBAY)
- AutoNation (AN) New Vehicle Comps up 8% in November
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!